

Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale

www.sesstim-orspaca.org

### Paul AVILLACH

Assistant Professor Harvard Medical School

Boston - USA

Plateformes de recherche translationnelle intégrant des données cliniques et omiques

janvier 2015

Cliquez ici pour voir l'intégralité des ressources associées à ce document

## Toward Precision Medicine: Building a patient centric information commons on common and rare diseases with I2b2/tranSMART

## Application to Autism and Phelan McDermid Syndrome

## Paul Avillach, MD, PhD

Assistant Professor - Harvard Medical School

Center of Biomedical Informatics Research Connection – Boston Children Hospital Medical-informatics - Erasmus MC University, Rotterdam, The Netherlands INSERM UMRS 872 eq 22, Paris, France





Disclosure:

Consultant for









Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Report from National academy of science, USA, 2011







Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Report from National academy of science, USA, 2011







### PI: Isaac Kohane – Harvard - CBMI







HARVARD MEDICAL SCHOOL TEACHING HOSPITAL





- Integrated platform to support translational research
- Initiated by Johnson & Johnson et Recombinant 6 years ago
   PI: Eric Perakslis
- Open-source since January 24<sup>th</sup>, 2012
- Installed at HEGP Hospital, Paris since May, 2012
- Today, driven and maintained by the tranSMART



http://transmartfoundation.org





OXFORD JOURNALS

# Briefings in **Bioinformatics**

# Translational research platforms integrating clinical and omics data: a review of publicly available solutions

Vincent Canuel\*, Bastien Rance\*, Paul Avillach, Patrice Degoulet and Anita Burgun

BRISK, caTRIP cBio Cancer Portal G-DOC

iCOD iDASH **tranSMART (i2b2)** 





### tranSMART main installations

- International Research Initiatives
  - IMI eTRIKS, EMIF
  - CTMM TralT
- Pharma & Biotech
  - Sanofi, Millennium, Pfizer, JNJ, Roche
- Government aligned Institutions
  - FDA
- Non-Profits
  - 1Mind4Research, Orion Bionetworks
- Hospitals / Academics
  - U Michigan, John's Hopkins, St. Jude, HEGP, Harvard/Boston Children Hospital
- Service Providers
  - Thomson Reuters,
     Recombinant(Deloitte), theHyve,
     Rancho Biosciences, BTGS

Start	Organization	Туре	Stage
2008	Johnson & Johnson	Pharma	Production
2008	Recombinant by Deloitte	Services	Multiple
2010	Sage Bionetworks	Non profit	Production
2010	Thomson Reuters	Services	Support
2010	U-BIOPRED	Consortium	Production
2011	SAFE-T	Consortium	Pilot
2011	University of Michigan,	Academic	Production
	(UMCCC)		
2012	APHP-HEGP Paris France	Academic	Production
2012	BT Cure	Consortium	Pilot
2012	CTMM/TralT	Consortium	Development
2012	FDA	Government	Development
2012	IMI/eTRIKS	Consortium	Development
2012	Merck	Pharma	Pilot
2012	Millennium Pharmaceuticals	Pharma	Production
2012	One Mind for Research (1M4R)	Non profit	Production
2012	Pfizer	Pharma	Production
2012	Roche	Pharma	Evaluation
2012	Sanofi-Aventis	Pharma	Development
2012	St. Jude	Non profit medical center	Development
2012	University of Michigan,	Academic	Development, Pilot
	Department of Computational		
2013	Agios	Biotechnology	Evaluation
2013	CARPEM – Cancer personalized	Academic French grant	Development
	medicine	8	
2013	Harvard Medical School /	Academic	Autism Pilot
	Boston Children Hospital		
2013	Boehringer Ingelheim	Pharma	Pilot
2013	Bristol Myers Squibb	Pharma	Evaluation
2013	BT Global Services	Services	Pilot
2013	Accelerated Cure Project for MS	Non profit	Development
	Personalized medicine and	Academic French gran	t Development
2014	colorectal cancers		
	PCORI PRRN Phelan-	Academic US grant	Development
	McDermid Syndrome Data		
2014	Network		







**Objectives**:

- **1. Integration** of clinical, biological and 'omics data in one place hypothesis free –
- 2. Generation of **hypothesis** by Clinicians / Researchers









Boston Children's Hospital Research Connection



# Autism cohorts Phenotype data

- Simons Simplex Collection (SSC) 2,760
- AGRE 3,300
- Autism Consortium (AC)

- 525
- Gene-Pheno studies Lou Kunkel HMS
  - Pre AC
  - AC
  - SSC





# **BIG** data

### [Bioinformatics & Integrative Genomics]







HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

+ many more

# Raw data

# RNA

SSC (928)	
Blood (Kunkel-Kohane)	
<ul> <li>Affymetrix Gene ST 1.0</li> </ul>	316
<ul> <li>Affymetrix U133+2</li> </ul>	19
– Illumina HiSeq	154
LCL (Geschwind)	
- Illumina REF-8 3.0	439
AC ( <b>166</b> )	
Blood (Kunkel-Kohane)	
<ul> <li>Affymetrix Gene ST 1.0</li> </ul>	117
<ul> <li>Affymetrix U133+2</li> </ul>	21
– Illumina HiSeq	28
BCH ( <b>386</b> )	
Blood (Kunkel-Kohane)	
<ul> <li>Affymetrix Gene ST 1.0</li> </ul>	186
<ul> <li>Affymetrix U133+2</li> </ul>	168
– Illumina HiSeq	32
AGRE ( <b>1,048</b> )	
LCL (Geschwind)	
- Illumina REF-8 3.0	1,048





# DNA

- Static genomic predisposition
  - Goal: enable streamlined analysis of genomic variation at any *functional unit* resolution
    - Single variant / variant type
    - Single gene
    - Gene set / pathway
    - Regulatory module
    - Cellular system
    - Genomic location / context
- Measurement types

. . .



# Raw genotyping array data by cohort

- SSC (3,184)
  - Ilumina Infinium1M
  - Illumina 1M Duo
- AC (60)
  - Affymetrix SNP 6.0
- AGRE (**3,832**)
  - Affymetrix 10K
  - Affymetrix 500K
  - Illumina HumanHap550
  - Illumina Infinium 1M





DNA

# WHOLE EXOME SEQUENCE data by cohort

- SSC (2,963)
  - State
- 914
- Illumina GAIIx
- Illumina HiSeq
- Eichler 676
  - Illumina GAIIx
  - Illumina HiSeq
- Wigler **1373** 
  - Illumina HiSeq
- AC (381)
  - Daly 381
    - Illumina HiSeq
- AGRE (1672)
  - Walsh 750
    - Illumina HiSeq
  - BI-BCM 922
    - Illumina HiSeq





# DNA



![](_page_18_Picture_1.jpeg)

![](_page_18_Picture_2.jpeg)

HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

![](_page_19_Picture_0.jpeg)

# Live DEMO

https://www.youtube.com/watch?v=rUFH697a2n4

![](_page_20_Picture_2.jpeg)

![](_page_20_Picture_3.jpeg)

Boston Children's Hospital Research Connection

![](_page_20_Picture_5.jpeg)

![](_page_20_Picture_6.jpeg)

![](_page_20_Picture_7.jpeg)

![](_page_21_Picture_0.jpeg)

![](_page_21_Picture_1.jpeg)

Boston Children's Hospital Research Connection

![](_page_21_Figure_3.jpeg)

![](_page_22_Figure_0.jpeg)

![](_page_22_Figure_1.jpeg)

![](_page_23_Picture_0.jpeg)

![](_page_23_Picture_1.jpeg)

# Phenome-Wide Association Studies on a Quantitative Trait: Application to TPMT Enzyme Activity and Thiopurine Therapy in Pharmacogenomics

Antoine Neuraz<sup>1,2</sup>, Laurent Chouchana<sup>3</sup>, Georgia Malamut<sup>4</sup>, Christine Le Beller<sup>5</sup>, Denis Roche<sup>6</sup>, Philippe Beaune<sup>3,6</sup>, Patrice Degoulet<sup>1,2</sup>, Anita Burgun<sup>1,2</sup>, Marie-Anne Loriot<sup>3,6</sup>, Paul Avillach<sup>1,2\*</sup>

1 Biomedical Informatics and Public Health Department, University Hospital HEGP, AP-HP, Paris, France, 2 INSERM UMR\_S 872 Team 22: Information Sciences to support Personalized Medicine, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France, 3 INSERM UMR-S 775, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 4 Gastroenterology Department, University Hospital HEGP, AP-HP, Paris, France, 5 Pharmacovigilance Center, University Hospital HEGP, AP-HP, Paris, France, 6 Biochemistry, Pharmacogenetics and Molecular Oncology Unit, University Hospital HEGP, AP-HP, Paris, France

![](_page_23_Picture_5.jpeg)

![](_page_23_Picture_6.jpeg)

![](_page_24_Picture_0.jpeg)

![](_page_24_Picture_1.jpeg)

![](_page_24_Picture_2.jpeg)

![](_page_25_Figure_0.jpeg)

# PCORI PPRN Grant

- Phelan-McDermid Syndrome Data Network
  - PI: Megan O'Boyle, Mother of PMS patient
  - Co-PI: Paul Avillach, MD, PhD
- Total: \$1M
- 18 months
- To collect all available patient data from Phelan-McDermid Syndrome (PMS) patients to make meaningful, well-annotated clinical data available to researchers and to share insights with members of the PCORI network

![](_page_26_Picture_7.jpeg)

![](_page_26_Picture_8.jpeg)

![](_page_27_Figure_0.jpeg)

![](_page_27_Picture_1.jpeg)

![](_page_27_Picture_2.jpeg)

![](_page_28_Picture_0.jpeg)

The Apache Software Foundation
 http://www.apache.org/

### $Box \ 1 \mid$ Natural language processing

Boundary detection	] [Fx	of obe	sity but no fx of cor	onary art	ery disea	ases.] [	
Tokenization	Fx   of   ol	oesity	but no  fx   of   c	oronary	artery	diseases   .	
Normalization		-		_	—	disease_	
Part-of-speech tagging	NN IN	NN	CC DT NN IN	JJ	NN	NNS	
Shallow parsing	NP PP	NP	NN	L	NP		
Entity recognition	Obesity		Coronary artery	disease	Cor	onary artery	
	Disease or diso UMLS ID: C002 Status: family h	rder 8754 istory	Disease or disord UMLS ID: C00100 Status: family his	ler )54 torv	Ana UM	atomy LS ID:C020504	42
	Negated: no	locory	Negated: yes	,			

Peter B. Jensen, Lars J. Jensen and Søren Brunak, Nat Rev Genet. 2012

TM

![](_page_28_Picture_5.jpeg)

![](_page_28_Picture_6.jpeg)

![](_page_29_Figure_0.jpeg)

Kohane I, Nature Review Gen. 2011

![](_page_29_Picture_2.jpeg)

![](_page_29_Picture_3.jpeg)

# Live Demo PMS\_DN

![](_page_30_Picture_1.jpeg)

![](_page_30_Picture_2.jpeg)

![](_page_31_Picture_0.jpeg)

Patient Centric Information Commons (PIC) PI: Isaac Kohane

![](_page_31_Figure_2.jpeg)

![](_page_31_Picture_3.jpeg)

![](_page_31_Picture_4.jpeg)

![](_page_32_Figure_0.jpeg)

![](_page_33_Picture_0.jpeg)

### **Autism Cohort**

![](_page_33_Picture_2.jpeg)

### CBMI / ResCon tranSMART team

Paul Avillach, MD, PhD Michael McDuffie, MS Ally Eran, PhD

#### Division of Developmental Medicine

Leonard Rappaport, MD, MS Ellen Hanson, PhD

#### BCH Division of Genetics & Genomics

Timothy Yu, MD, PhD Ingrid Holm, MD, MPH Stephanie Brewster, MS, CGC Joanna Reinwald, MS, GC Frank Jackson

### Laboratory of cognitive neuroscience

Charles Nelson, PhD Vanessa Vogel-Farley Nicole Coman

#### **The Research Connection**

Wendy Wolf, PhD Sarah Savage, MS, CGC Catherine Clinton, MS, CGC Tram Tran

#### CBMI

Eric D Perakslis, PhD Alexa T. McCray, PhD Dennis Wall, PhD Nathan Palmer, PhD Sek Won Kong, MD Finale Doshi-Velez, PhD

### i2b2 / Partners

Shawn Murphy, MD, PhD Lori Phillips, Ms Michael Mendis

#### **Principal Investigators**

Isaac Kohane, MD, PhD Louis Kunkel, PhD David Margulies, MD Jonathan Bickel, MD, MS Paul Avillach, MD, PhD

## Business Intelligence and Clinical Research Informatics

Mohamad Daniar Nandan Patibandla Rick Agrella Paul OByrne Lynne N. Alley Gina Bianco

#### **Clinical NLP**

Guergana Savova, PhD - PI Chen Lin Dmitriy Dligach, PhD Pei Chen Sameer Pradhan, PhD Sean Finan Timothy Miller, PhD

# PMS\_DN team

- Megan O'Boyle, PI & Mom of Shannon
- Paul Avillach, MD, PhD , Co-PI, Harvard Medical School
- Liz Horn, PhD, Co-PI, Network Director

### PMSF Research director

• Geraldine Bliss, MSc & Mom of

### Project Manager

Andria Cornell Mann

### LGC Data Network Specialist

Rebecca Davis

### Family Engagement Specialist

Jackie Malasky

### Harvard Medical School : CBMI

- Sushma Hanawal
- Michael McDuffie, MSc
- Isaac Kohane, MD, PhD
- Eric Perakslis, PhD

### Boston Children's Hospital: cTAKES NLP

- Guergana Savova, PhD
- Pei Chen

### Harvard Medical School : IT Infrastructure Support

- Christopher Botka
- David Hummel
- Daniel Lewis

![](_page_34_Picture_24.jpeg)

![](_page_34_Picture_26.jpeg)

![](_page_35_Picture_0.jpeg)

![](_page_35_Picture_1.jpeg)

# **Additional slides**

![](_page_36_Picture_1.jpeg)

![](_page_36_Picture_2.jpeg)

## SHRINE: Enabling Nationally Scalable Multi-Site Disease Studies

Andrew J. McMurry<sup>1,2,3,4</sup>\*, Shawn N. Murphy<sup>3,5,6</sup>, Douglas MacFadden<sup>1</sup>, Griffin Weber<sup>3,7</sup>, William W. Simons<sup>1</sup>, John Orechia<sup>8</sup>, Jonathan Bickel<sup>2,9</sup>, Nich Wattanasin<sup>5</sup>, Clint Gilbert<sup>1</sup>, Philip Trevvett<sup>1</sup>, Susanne Churchill<sup>3,5</sup>, Isaac S. Kohane<sup>1,2,3</sup>

![](_page_37_Picture_4.jpeg)

![](_page_37_Figure_5.jpeg)

![](_page_37_Picture_6.jpeg)

Query	Tool							8 P -
Query N	lame:							
	Group 1	×		Group 2	×		Group 3	×
Dates	Occurs > 0x	Exclude	Dates	Occurs > 0x	Exclude	Dates	Occurs > 0x	Exclude
Acute lymphoid leukemia ir Acute lymphoid leukemia w Vincristine Sulfate Vincristine Sulfate Vincristine Sulfate Vincristine Sulfate Occuptor Vincristine Hydrochloride Vincristine Sulfate Occuptor Vincristine Sulfate Oc								
	)	) + +						
SHRIN	E Demo				-	Info	Request New	w Topic
Run Q	uery New C	Query P	Print Que	ry 3 Group	os [		New Group	
Query Status								
Hospital A32±3PatientsHospital B264±3PatientsHospital C815±3PatientsHospital D223±3PatientsAggregated1134±12Patients								

![](_page_38_Figure_0.jpeg)

![](_page_38_Picture_1.jpeg)

![](_page_38_Picture_2.jpeg)

![](_page_39_Figure_0.jpeg)

![](_page_39_Picture_1.jpeg)

![](_page_39_Picture_2.jpeg)

![](_page_40_Picture_0.jpeg)

![](_page_41_Picture_0.jpeg)

Patient Centric Information Commons (PIC) PI: Isaac Kohane

![](_page_41_Figure_2.jpeg)

![](_page_41_Picture_3.jpeg)

![](_page_41_Picture_4.jpeg)

![](_page_42_Picture_0.jpeg)

### Patient Centric Information Commons (PIC)

Sandbox: Neurodevelopment Disorders PICIs (NDD PICIs)

- DRAFT -Oct 3rd 2014

![](_page_42_Figure_4.jpeg)

![](_page_43_Figure_0.jpeg)

![](_page_44_Figure_0.jpeg)

Very High TPMT activity vs others

![](_page_45_Figure_1.jpeg)

![](_page_46_Figure_0.jpeg)

![](_page_47_Picture_0.jpeg)

![](_page_47_Picture_1.jpeg)

![](_page_47_Picture_2.jpeg)

Please login		
Login ID:	admin	
Password:	•••••	
	Login	
Not a user? Co	ontact administrator to request an account	

This application has been secured using standards published by the Harvard University Information Technology (HUIT) group.

![](_page_47_Picture_5.jpeg)

![](_page_47_Picture_6.jpeg)

![](_page_47_Picture_7.jpeg)

![](_page_48_Picture_0.jpeg)

Patient consent(s)

• EHR longitudinal data

Expression Arrays

- Clinical Cohorts
  - WES data

![](_page_49_Figure_0.jpeg)

![](_page_50_Figure_0.jpeg)

![](_page_50_Picture_1.jpeg)

![](_page_50_Picture_2.jpeg)

# **Biobank Explorer**

#### □ Facility: Broad Institute (94 Items)

Genotyping	Broad Institute	Pre Autism Consortium	м	Affymetrix	0	250	129.914	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	м	Affymetrix	1	500	144.25	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	F	Affymetrix	0	250	144.947	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	м	Affymetrix	0	250	91.174	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	М	Affymetrix	1	250	81.704	gDNA	contact@mit 1 🔗
Genotyping	Broad Institute	Pre Autism Consortium	F	Affymetrix	0	250	166.833	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	М	Affymetrix	0	250	158.328	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	м	Affymetrix	1	250	42.482	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	F	Affymetrix	0	250	130.192	gDNA	contact@mit 1 🔗
Genotyping	Broad Institute	Pre Autism Consortium	м	Affymetrix	0	250	99.026	gDNA	contact@mit 1
Genotyping	Broad Institute	Pre Autism Consortium	F	Affymetrix	1	250	32.267	gDNA	contact@mit 1 🔗
Genotyping	Broad Institute	Pre Autism Consortium	F	Affymetrix	0	250	144.832	gDNA	contact@mit 1

![](_page_51_Picture_3.jpeg)

![](_page_51_Picture_4.jpeg)

### **Gene Function**

#### By FUNC\_REFGENE

exonic (258834)
 exonic;splicing (32)
 intergenic (159)
 intronic (106)
 splicing (55)

#### By EXONICFUNC\_KNOWNGENE

NA (168)
 nonsynonymous SNV (258760)
 stopgain SNV (65)
 stoploss SNV (28)
 unknown (165)

# By EXONICFUNC\_REFGENE NA (320) nonsynonymous SNV (257983)

stopgain SNV (1) unknown (882)

#### By FUNC\_ENSGENE

exonic (259026) exonic;splicing (112) intergenic (47) ncRNA\_exonic (1)

### By FUNC\_KNOWNGENE

exonic (258929)
 exonic;splicing (89)
 intergenic (40)
 intronic (45)
 ncRNA\_exonic (83)

#### By EXONICFUNC\_ENSGENE

NA (48)
 nonsynonymous SNV (258865)
 stopgain SNV (95)
 stoploss SNV (80)
 unknown (98)

#### Gene Name

### By GENE\_REFGENE

![](_page_52_Picture_15.jpeg)

### **Functional Prediction Scores**

By LJB2_SIFT		
- < +	Filter	
By LJB2_LRT		

C < \$
--------

Ву	LJB2_	FATHMM		
	< ÷		Filter	

By LJB2	SIPHY	
□ < ≑	Filter	

### **Functional Prediction**

By LJB2\_PP2\_HDIV\_PRED B (189161)

By	LJB2	POLYPHEN2_HDIV
	< \$	Filter

Ву	LJB2_	MUTATIONTASTER
0	< \$	Filter

By LJB2_G	ERP
□ < ≑	Filter

By GENE_	ENSGENE	

Ву	LJB2_	POLYPHEN2_HVAR
$\Box$	< ‡	Filter

By LJB_M	JTATIONASSESSOR
< +	Filter

Ву	LJB2_	PHYLOP	
	< ÷		Filter

By LJB2\_POLYPHEN2\_HVAR\_PRED B (209991) By LJB2\_LRT\_PRED D (39237)

# **Genome Variant Explorer**

CHROMOSOME: (chr21), REFGENE EXONIC_FUNCTION: (nonsynonymous SNV), POLYPHEN 2_HDIV > .9										
CHROMOSOME	REFERENCE	OBSERVED_A	ZYGOSITY	REFGENE_GE	REFGENE_EX	REFGENE_AA	VCF_GENOTY	POLYPHEN_2	POLYPHEN_2	Variant Count 🔺
chr21	G	A	het	COL6A1	nonsynonymous SNV	COL6A1	0/1	1.0	D	1
chr21	т	С	het	KRTAP10-12	nonsynonymous SNV	KRTAP10-12	0/1	0.986	D	1
chr21	т	С	het	KRTAP10-11	nonsynonymous SNV	KRTAP10-11	0/1	1.0	D	1
chr21	G	A	hom	KRTAP10-10	nonsynonymous SNV	KRTAP10-10	1/1	0.998	D	1
chr21	G	A	hom	KRTAP10-6	nonsynonymous SNV	KRTAP10-6	1/1	1.0	D	1
chr21	С	т	het	KRTAP10-5	nonsynonymous SNV	KRTAP10-5	0/1	0.903	Ρ	1
chr21	С	т	hom	KRTAP10-5	nonsynonymous SNV	KRTAP10-5	1/1	0.903	Ρ	1
chr21	т	G	hom	KRTAP10-4	nonsynonymous SNV	KRTAP10-4	1/1	0.928	Ρ	1
chr21	G	Α	het	AIRE	nonsynonymous SNV	AIRE	0/1	0.999	D	1
chr21	т	С	het	DSCAM	nonsynonymous SNV	DSCAM	0/1	0.958	D	1

![](_page_53_Picture_2.jpeg)

![](_page_53_Picture_3.jpeg)

![](_page_54_Picture_0.jpeg)

![](_page_54_Picture_1.jpeg)

![](_page_54_Picture_2.jpeg)

Please login	
Login ID:	admin
Password:	•••••
	Login
Not a user? Co	ontact administrator to request an account

This application has been secured using standards published by the Harvard University Information Technology (HUIT) group.

![](_page_54_Picture_5.jpeg)

![](_page_54_Picture_6.jpeg)

![](_page_54_Picture_7.jpeg)

![](_page_55_Figure_0.jpeg)

![](_page_55_Picture_1.jpeg)

![](_page_55_Picture_2.jpeg)

![](_page_56_Figure_0.jpeg)

![](_page_56_Picture_2.jpeg)

![](_page_57_Figure_0.jpeg)

![](_page_58_Picture_0.jpeg)

![](_page_58_Picture_1.jpeg)

VOLUME 27 · NUMBER 35 · DECEMBER 10 2009

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

## Analysis of *PTEN*, *BRAF*, and *EGFR* Status in Determining Benefit From Cetuximab Therapy in Wild-Type *KRAS* Metastatic Colon Cancer

Pierre Laurent-Puig, Anne Cayre, Gilles Manceau, Emmanuel Buc, Jean-Baptiste Bachet, Thierry Lecomte, Philippe Rougier, Astrid Lievre, Bruno Landi, Valérie Boige, Michel Ducreux, Marc Ychou, Fréderic Bibeau, Olivier Bouché, Julia Reid, Steven Stone, and Frédérique Penault-Llorca

![](_page_58_Picture_7.jpeg)

![](_page_58_Picture_8.jpeg)

![](_page_59_Figure_0.jpeg)

![](_page_59_Picture_1.jpeg)

![](_page_59_Picture_2.jpeg)

# transmart

![](_page_60_Figure_1.jpeg)

### HEGP: Canuel V, Avillach P

![](_page_60_Picture_3.jpeg)

![](_page_60_Picture_4.jpeg)

HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

![](_page_61_Figure_0.jpeg)

HEGP: Canuel V, Avillach P

![](_page_61_Picture_2.jpeg)

![](_page_61_Picture_3.jpeg)

HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

				Nutati	BILAN														
NÂ⁰inter				on	MUT			Meilleure				délai survie		EGFR copy		Mutation			
e ADN	Age	iexe	BILANKRAS	BRAF	NRAS	nbligne	Toxicit	reponse	Progression	Duree rep	DécÃ⁻s	globale	OMS	number	Score de HIRSCH	<b>PIK3CA</b>	PTEN_CYTO	PTEN_MB	PTEN_NX
1		М		NM	NM	1	2	1	1	58.14	oui	26.3	1	10	positif	NM	80	20	20
5	71	М	NM	NM	NM	6	2	2	1	46	oui	21.6	1	3	negatif	NM	200	10	140
6	44	F	NM	NM	NM	4	2	2	1	67.14	oui	48.13	0	3	negatif	м	60	30	0
7	72	М	м	NM	NM	4	1	2	0	48	non	40.4	1	2.1	negatif	NM	160	0	80
8	48	М		NM		6	2	2	1	34.43	oui	13.87	1	11	positif	NM	0	0	60
9	55	F	NM	NM	NM	3	1	2	1	32	oui	15.07	2	3.4	negatif	NM	10	40	0
10	64	F	NM	NM	NM	2	1	2	0	17.1	oui	20.03	0	2.5	negatif	NM	260	20	150
11	62	М	NM	NM	NM	3	2	2	1	52	oui	24.23	1	2.8	negatif	NM	200	0	0
12	50	М	NM	NM	NM	3	2	3	1	14.71	oui	9.6	0	2.9	negatif	NM	160	0	130
13	54	М	м	NM	NM	2	2	3	1	20	oui	6.93	2		negatif	NM	130	0	100
14	73	F	M	NM	NM	3	1	3	1	19.29	oui	20.03	0		negatif	М	230	0	110
15	71	М	M	NM	NM	2	1	3	1	16	oui	13.47	0		negatif	NM	50	10	0
16	53	F	M	NM	NM	3	2	3	1	20	oui	10.73	1		negatif	NM	10	30	0
18	78	М	м	NM	NM	2	1	4	1	11.14	oui	16.33	0	2.4	negatif	М	200	0	50
19	51	F	M	NM	NM	2	1	4	1	4.43	oui	1.3	3		negatif	M	80	0	120
20	75	F	NM	NM	NM	3	0	4	1	7.86	oui	6	0	2.3	negatif	м	60	0	80
21	69	М	M	NM	NM	2	2	4	1	9.57	oui	10.7	1		negatif	NM	10	0	40
22	72	М	M	NM	NM	4	0	4	1	6.14	oui	2.07	1		negatif	M	190	0	50
23	61	F	NM	NM	NM	2	2	4	1	12	oui	10.33	1	2.3	negatif	M	75	50	10
24	53	М	м	NM	NM	5	2	4	1	9	oui	9.8	1		negatif	NM	0	0	0
25	59	М	м	NM	NM	2	1	4	1	8.57	oui	3.57	0		negatif	NM	240	0	120
26	75	М	м	NM	NM	2	1	4	1	8	oui	6.4	1		negatif	NM	0	0	120
27	58	F	M	NM	NM	6	2	4	1	8	oui	8.93	0		positif	NM	10	50	0
28	47	М	NM	NM	NM	3	3	4	1	8	oui	5.63	0	3.3	negatif	NM	10	0	0
30	60	F	M	NM	NM	3	1	4	1	8	oui	3.77	1		negatif	NM	5	0	0
31	58	F	NM	NM	NM	4	2	3	1	17.57	oui	7.2	2	3.2	negatif	NM	40	0	60
32	58	М	NM	NM	NM	2	3	2	0	33	non	26.97	1			NM	0	0	0
33	67	М	M	NM	NM	3	2	3	1	29.71	oui	13	2			NM	100	0	30
34	68	М	NM	NM	NM	2	2	2	1	33.14	oui	22.17	1			NM	0	0	0
35	59	F	NM	NM	NM	2	1	2	0	31.9	oui	11.83	1			NM	0	0	0
36	61	F	M	NM	NM	4	0	4	1	3	oui	2.8	0			NM			
37	57	М	NM	NM	NM	3	1	3	1	17.43	oui	5.1	1			NM			
38	77	F	M	NM	NM	3	0	3	1	21.57	oui	7.83	1			NM			
39	63	F	M	NM	NM	4	0	4	1	6.14	oui	5.57	1			NM			
42	60	F	M	NM	NM	2	1	4	1	12	oui	5.1	1		negatif	NM	150	0	200
43	60	F	M	NM	NM	2	2	3	0	24	oui	16.77	0		negatif	NM	40	0	160
44	59	F	NM	NM	NM	2	2	3	1	34	oui	7.93	1	2.4	negatif	M	90	0	120

![](_page_62_Picture_1.jpeg)

![](_page_62_Picture_2.jpeg)

Filename	Category Code	Column Number	Data Label	Data Label Sourc	Controlled Vocab Cd
EGP0001_data.csv		1	SUBL ID		
EGP0001_data.csv	Clinical_Data+Demographics	2	AGE		424144002
EGP0001_data.csv	Clinical Data+Demographics	3	ISEX		263495000
EGP0001_data.csv	Biomarker_Data+Non_Omics+Mutation_Detection	4	KRAS Mutation		190070
EGP0001_data.csv	Biomarker_Data+Non_Omics+Mutation_Detection	5	BRAF Mutation		164757
EGP0001_data.csv	Biomarker_Data+Non_Omics+Mutation_Detection	6	NRAS Mutation		164790
EGP0001_data.csv	Clinical_Data+Treatment+Chemotherapy	7	Number of lines		399042005
EGP0001_data.csv		8	OMIT		
EGP0001_data.csv		9	OMIT		
EGP0001_data.csv	Clinical_Data+Outcome	10	Progression		419835002
EGP0001_data.csv	Clinical_Data+Outcome	11	Duration of Response		445397003
EGP0001_data.csv	Clinical_Data+Outcome	12	Death		419620001
EGP0001_data.csv	Clinical_Data+Outcome	13	Overall Survival		445320007
EGP0001_data.csv	Clinical_Data+Outcome	14	OMS Score		373802001
EGP0001_data.csv	Biomarker_Data+Non_Omics+Immunological	15	EGFR Copy Number		5006
EGP0001_data.csv	Biomarker_Data+Non_Omics+Immunological	16	HIRSCH Score		
EGP0001_data.csv	Biomarker_Data+Non_Omics+Immunological	17	PIK3CA Mutation		171834
EGP0001_data.csv	Biomarker_Data+Non_Omics+Immunological	18			
EGP0001_data.csv	Biomarker_Data+Non_Omics+Immunological	19			
EGP0001_data.csv	Biomarker_Data+Non_Omics+Immunological	20			

![](_page_63_Picture_1.jpeg)

![](_page_63_Picture_2.jpeg)

![](_page_63_Picture_3.jpeg)

![](_page_64_Figure_0.jpeg)

![](_page_65_Figure_0.jpeg)

![](_page_65_Figure_1.jpeg)

![](_page_65_Figure_2.jpeg)

HEGP: Canuel V, Avillach P

![](_page_65_Picture_4.jpeg)